AUPQ232599A0 - Drug for treating fractures - Google Patents

Drug for treating fractures

Info

Publication number
AUPQ232599A0
AUPQ232599A0 AUPQ2325A AUPQ232599A AUPQ232599A0 AU PQ232599 A0 AUPQ232599 A0 AU PQ232599A0 AU PQ2325 A AUPQ2325 A AU PQ2325A AU PQ232599 A AUPQ232599 A AU PQ232599A AU PQ232599 A0 AUPQ232599 A0 AU PQ232599A0
Authority
AU
Australia
Prior art keywords
drug
treating fractures
fractures
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ2325A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Royal Alexandra Hospital for Children
Original Assignee
ROYAL ALEXANDER HOSPITAL FOR C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROYAL ALEXANDER HOSPITAL FOR C filed Critical ROYAL ALEXANDER HOSPITAL FOR C
Priority to AUPQ2325A priority Critical patent/AUPQ232599A0/en
Publication of AUPQ232599A0 publication Critical patent/AUPQ232599A0/en
Priority to AU65488/00A priority patent/AU781068B2/en
Priority to PCT/AU2000/000982 priority patent/WO2001013922A1/en
Priority to IL14816600A priority patent/IL148166A0/xx
Priority to CA002381302A priority patent/CA2381302A1/en
Priority to CNB008117659A priority patent/CN100345548C/zh
Priority to NZ517538A priority patent/NZ517538A/en
Priority to BR0013416-3A priority patent/BR0013416A/pt
Priority to JP2001518059A priority patent/JP2003507426A/ja
Priority to SK238-2002A priority patent/SK2382002A3/sk
Priority to HU0202396A priority patent/HUP0202396A3/hu
Priority to KR1020027002160A priority patent/KR20020027562A/ko
Priority to EP00952791A priority patent/EP1214079A4/en
Priority to PL00353485A priority patent/PL353485A1/xx
Priority to NO20020784A priority patent/NO20020784L/no
Priority to ZA200202160A priority patent/ZA200202160B/en
Priority to HK03100502.8A priority patent/HK1048441B/zh
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AUPQ2325A 1999-08-19 1999-08-19 Drug for treating fractures Abandoned AUPQ232599A0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures
PL00353485A PL353485A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures
JP2001518059A JP2003507426A (ja) 1999-08-19 2000-08-17 骨折治療薬
HU0202396A HUP0202396A3 (en) 1999-08-19 2000-08-17 Medicaments useful for treating fractures
IL14816600A IL148166A0 (en) 1999-08-19 2000-08-17 Drug for treating fractures
CA002381302A CA2381302A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures
CNB008117659A CN100345548C (zh) 1999-08-19 2000-08-17 用于治疗骨折的药物
NZ517538A NZ517538A (en) 1999-08-19 2000-08-17 Drug for treating fractures
BR0013416-3A BR0013416A (pt) 1999-08-19 2000-08-17 Droga, uso de uma droga selecionada do grupo que consiste de pelo menos um bisfosfonato, e, método para tratamento de um osso fraturado
AU65488/00A AU781068B2 (en) 1999-08-19 2000-08-17 Drug for treating fractures
SK238-2002A SK2382002A3 (en) 1999-08-19 2000-08-17 Drug for treating fractures
PCT/AU2000/000982 WO2001013922A1 (en) 1999-08-19 2000-08-17 Drug for treating fractures
KR1020027002160A KR20020027562A (ko) 1999-08-19 2000-08-17 골절 치료용 약제
EP00952791A EP1214079A4 (en) 1999-08-19 2000-08-17 MEDICINES FOR TREATING FRACTURES
NO20020784A NO20020784L (no) 1999-08-19 2002-02-18 Medikament for behandling av brudd
ZA200202160A ZA200202160B (en) 1999-08-19 2002-03-15 Drug for treating fractures.
HK03100502.8A HK1048441B (zh) 1999-08-19 2003-01-21 用於治療骨折的藥物

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ2325A AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures

Publications (1)

Publication Number Publication Date
AUPQ232599A0 true AUPQ232599A0 (en) 1999-09-09

Family

ID=3816500

Family Applications (1)

Application Number Title Priority Date Filing Date
AUPQ2325A Abandoned AUPQ232599A0 (en) 1999-08-19 1999-08-19 Drug for treating fractures

Country Status (16)

Country Link
EP (1) EP1214079A4 (hu)
JP (1) JP2003507426A (hu)
KR (1) KR20020027562A (hu)
CN (1) CN100345548C (hu)
AU (1) AUPQ232599A0 (hu)
BR (1) BR0013416A (hu)
CA (1) CA2381302A1 (hu)
HK (1) HK1048441B (hu)
HU (1) HUP0202396A3 (hu)
IL (1) IL148166A0 (hu)
NO (1) NO20020784L (hu)
NZ (1) NZ517538A (hu)
PL (1) PL353485A1 (hu)
SK (1) SK2382002A3 (hu)
WO (1) WO2001013922A1 (hu)
ZA (1) ZA200202160B (hu)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0116862A (pt) 2001-02-06 2004-01-13 Royal Alexandra Hosp Children Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans
WO2002080933A1 (en) * 2001-04-03 2002-10-17 The Royal Alexandra Hospital For Children A drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
ES2561463T3 (es) * 2003-08-21 2016-02-26 Addbio Ab Dispositivo de implante recubierto con bisfosfonato y método para el mismo
NZ545804A (en) * 2003-09-19 2009-09-25 Wisconsin Alumni Res Found Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
ITMI20040218A1 (it) * 2004-02-10 2004-05-10 Abiogen Pharma Spa Uso di neridronato sodico per promuovere la neoformazione ossea
ITMI20040641A1 (it) * 2004-03-31 2004-06-30 Tb Technology S R L Composizioni bioadesive bifunzionali per implantologia orale
AR048742A1 (es) * 2004-12-22 2006-05-24 Gador Sa Sistema de aplicacion de medicamentos intra-oral
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
CN114532937A (zh) * 2020-11-18 2022-05-27 中国人民解放军海军军医大学第一附属医院 一种小肠镜辅助装置

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8107560A (pt) * 1981-11-19 1983-07-05 Luiz Romariz Duarte Estimulacao ultra-sonica da consolidacao de fraturas osseas
JPH07502507A (ja) * 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
AU670337B2 (en) * 1992-11-30 1996-07-11 Novartis Ag Use of certain methanebisphosphonic acid derivatives in fracture healing
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
EP0675723A4 (en) * 1992-12-23 1998-08-05 Merck & Co Inc BIPHOSPHONATE / ESTROGEN THERAPY FOR TREATING AND PREVENTING BONE LOSS.
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
GB9613722D0 (en) * 1996-06-28 1996-08-28 Univ Liverpool Chemical compounds

Also Published As

Publication number Publication date
NO20020784D0 (no) 2002-02-18
PL353485A1 (en) 2003-11-17
HK1048441B (zh) 2008-02-22
BR0013416A (pt) 2002-04-30
HK1048441A1 (en) 2003-04-04
JP2003507426A (ja) 2003-02-25
NO20020784L (no) 2002-02-18
HUP0202396A2 (hu) 2002-11-28
CN100345548C (zh) 2007-10-31
CA2381302A1 (en) 2001-03-01
WO2001013922A1 (en) 2001-03-01
EP1214079A4 (en) 2004-03-24
EP1214079A1 (en) 2002-06-19
ZA200202160B (en) 2003-08-27
CN1370071A (zh) 2002-09-18
HUP0202396A3 (en) 2005-02-28
NZ517538A (en) 2003-07-25
KR20020027562A (ko) 2002-04-13
SK2382002A3 (en) 2002-09-10
IL148166A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
AU7842500A (en) System for orthopedic treatment
AU6777300A (en) Treatment apparatus for wounds
AU5602500A (en) System for orthopedic treatment protocol
HUP0200556A2 (en) Medicament for treating diabetes
AU5259100A (en) Medicament
AU1050401A (en) Device for cardiac therapy
AU6908500A (en) Treatment for narcolepsy
IL138784A0 (en) Treatment for diabetes
AU5089400A (en) Arthritis treatment
AU2002210462A1 (en) Transdermal therapeutic system for treating restless-legs-syndrome
AU773240C (en) Medicament for treating hypertension
AUPQ232599A0 (en) Drug for treating fractures
AU4770800A (en) Body treatment product
AU5547000A (en) Novel treatment
AU2266801A (en) Combination therapy for treating neurodegenerative disease
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
AU4556800A (en) Novel treatment
AU1972200A (en) Treatment for fabrics
AU3988099A (en) Combination therapy for treating hypercholesterolemia
AU1618901A (en) Treatment of rosacea
AU5847299A (en) Medical device for treating narrow nostrils
AU1036801A (en) Agent for treating cephalic pain
AU5379200A (en) Bone stimulating factor
HU9902296D0 (en) Pharmaceutical composition for treating caltification
AU2616201A (en) Cancer treatment method

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 6548800

Country of ref document: AU